A SHORT HiSTORY OF THe CLiNiCAL USeS OF HUMAN TeRM PLACeNTA
Human placenta has been traditionally used in Chinese medicine for centuries. The Compendium of Materia Medica was published in 1593 by one of the first and greatest biologists and pharmaceutical experts of China, Li Shi-Zhen (Figure 1 ). This medical text is a Chinese record of substances with medical properties, and it contains a section entirely devoted to the medical uses of human placenta "zi he chi" as a medicine (Young and Benyshek, 2010) . At that time, eating the placenta was thought to be beneficial but since then there has been a shift of paradigms in which scientific rationale supports clinical benefit of placental tissues, or derivatives, for treating patients afflicted by a variety of diseases. As discussed below, the earliest reported applications of the placenta (after Li Shi-Zhen's) were focused on fetal membranes. The first reports showing that the placenta also harbors cells, which could have stem/progenitor properties, ultimately giving rise to their potential use in regenerative medicine, were published many years later (Figure 1) , (Bailo et al., 2004; Fukuchi et al., 2004; Igura et al., 2004; In 't Anker et al., 2004; Soncini et al., 2007; Troyer and Weiss, 2008) .
The first documented use of fetal membranes as a surgical material in skin transplantation came more than 3 decades after the placenta was initially reported to possess medicinal properties. In 1910, Davis (1910) showed that the use of amniotic membrane (AM) in skin grafting gave superior results when compared to xenograft or cadaveric coverings. Shortly afterwards in 1913 , Stern (1913 and Sabella (1913) reported the use of the AM for treating skin wounds. They applied intact amniotic tissues to skin burns and ulcers and then covered them with dressings. Upon removal of the dressings 2 days later, the authors reported that the amnion had integrated with the patient's tissues. They also reported lack of infection, a significant decrease in pain, and an increased rate of re-epithelialization of the traumatized skin surface in patients treated with amnion.
More than 20 years passed before another study would report the use of amniotic tissues for wound repair or surgery. Around 1940, the AM was increasingly being used successfully in different applications. In the late 1930s, Brindeau (1934) and Burger (1937) reported the successful use of amnion for vaginal reconstruction surgery in a patient with Mullerian agenesis. Shortly afterwards, the AM was first applied in ophthalmology to repair conjunctival defects (De Rotth, 1940) and burns (Sorsby and Symons, 1946; Sorsby et al., 1947) . Ophthalmology would later go on to be one of the most popular applications of the AM to date.
Following these and other studies, between 1940 and 1970, a number of clinical trials were published reconfirming the successful use of the AM for skin injuries. In 1940, the first paper was published describing the use of amnion for the prevention of meningocerebral adhesions following head injury. The authors reported lack of adhesions and lack of rejection 60 days after surgery, and "disappearance" of the amnion after 30 days (Chao et al., 1940) . Later that decade, and following Burger's work on vaginal reconstruction, Kubanyi (1947) used amnion in patients undergoing abdominal surgery with an enterocutaneus fistula secondary to surgery for lysis of adhesions. After closing the small bowel fistula, the small area of the bowel was wrapped with amnion, and notably, patients were discharged on a regular diet only 12 days after surgery. Importantly, Dino et al. (1965) showed that AM from routine deliveries could be sterilized and kept for 1 Chinese medical text published in 1593 by Li Shi-Zhen; 2 Davis (1910) and Stern (1913) and Sabella (1913) ; 3 Brindeau (1934) and Burger (1937); 4 De Rotth (1940) , Sorsby and Symons (1946) ; Sorsby et al. (1947) ; 5 Dino et al. (1965) ; 6 Trelford-Sauder et al. (1977) ; Trelford-Sauder et al. (1978) , Silverton et al. (1979) ; Dhall (1984) , Nisolle and Donnez (1992) , Georgy and Aziz (1996) , Gharib et al. (1996) ; 7 Trelford-Sauder et al. (1978) ; Muralidharan et al. (1991) , Young et al. (1991) ; Arora et al. (1994) , Rennekampff et al. (1994); 8 Troensagaard-Hansen (1950); Bennett et al. (1980) , Subrahmanyam (1995) ; 9 Gruss and Jirsch (1978) and Bose (1979) ; 10 Lee and Tseng (1997); Tseng et al. (1997) , 11, 12 reviewed in Fetterolf and Snyder (2012) .
6 weeks at 4°C and safely used on acute second degree burns and on skin donor sites (Dino et al., 1965) . This was one of the first reports which suggested handling procedures for the AM, which in turn fueled even more interest among clinicians in using the AM for treating skin lesions.
In 1972, Trelford et al. (1972) used human amnion in sheep, and confirmed previous findings that as a surface graft, amnion was able to reduce pain, decrease infection, and reduce the loss of fluids. Also in 1972, Robson and his colleagues began to study the use of AM for severe burns and skin injuries. Similar to Trelford, they reported notable pain relief and immediate adherence of the AM dressing to the wound. Interestingly, the membranes were easily peeled off 1 week after application and, according to Robson, spontaneous re-epithelialization had occurred underneath the membranes. Later that decade, in 1977, Trelford-Sauder et al. (1977) reported the successful use of amnion to replace pelvic peritoneum in patients who had exenterative procedures. Following these and other observations, there was an exponential increase of published clinical studies, which reconfirmed the successful application of fetal membranes in diverse clinical indications, including burns (Gruss and Jirsch, 1978; Bose, 1979 ), ulcers (Troensagaard-Hansen, 1950 Bennett et al., 1980; Subrahmanyam, 1995) , surgical reconstruction of the vagina (Dhall, 1984; Nisolle and Donnez, 1992; Georgy and Aziz, 1996) , abdominal surgery (Trelford-Sauder et al., 1978; Silverton et al., 1979; Gharib et al., 1996) , and other surgical procedures for the prevention of adhesions (Trelford-Sauder et al., 1978; Muralidharan et al., 1991; Young et al., 1991; Arora et al., 1994; Rennekampff et al., 1994) .
The 1990s can be considered the beginning of modern history on the use of AM in ophthalmology (Dua et al., 2004) . In this decade, Dr. Tseng, an ophthalmologist from Miami, applied for Human Cell Tissue Products (HCT/P) regulatory status for the use of amniotic tissues in ocular repair. In 1999, Dr. Tseng's proposal was rejected by the US Food and Drug Administration's (FDA) tissue reference group stating "Amniotic membrane for ocular surface reconstruction is considered a tissue under the current code of federal regulations (CFR) at 21 CFR Part 1270, but the intended use would be non-homologous when 21 CFR Part 1271 becomes effective" Tseng et al., 1997) . Dr. Tseng appealed the ruling and 1 year later, the FDA reversed the prior ruling stating that "Allogeneic amniotic membrane for ocular repair is considered to be a section 361 HCT/P if the product's advertising is restricted to homologous use for wound covering. " The two main points made by the FDA were that it had to be used as a covering and must be acellular, whereas "Amniotic membrane cultured with stem cells for ocular repair is considered to be a biologic product subject to Investigational New Drug and Biologic License Application. " From that point on, the use of AM in ophthalmic surgery catapulted. Nowadays, there are over 45,000 applications used by the ophthalmologists, including conjunctival reconstruction, burn treatment, glaucoma surgery, and wound healing (Fetterolf and Snyder, 2012) .
CURReNT CLiNiCAL APPLiCATiONS OF PLACeNTA
The twenty-first century marks another turning point in which the use of cells isolated from different placental regions are being progressively more investigated and used for their therapeutic potential. These studies have paved the way for what are now considered established clinical uses and investigative clinical trials. Placental tissues, and cells derived thereof, are nowadays interesting therapeutic biomaterials currently used in the clinic. The renewed interest in using the AM in a number of applications has been favored by the development of improved techniques for both membrane cryopreservation and advanced isolation and culture procedures for cells derived thereof.
established Clinical Applications
Recent advances in tissue preservation techniques, accompanied by evidence of therapeutic effects, have resulted in commercially available AM products for use in patients. A repertoire of data shows that these products promote rapid and complete healing of wounds.
Without a doubt, the AM is widely utilized in the field of ophthalmology. The AM is routinely used as a graft, spread onto the ocular surface to treat epithelial defects or ulcers, or as a bandage to cover the ocular surface to promote healing. An infinite number of ocular pathologies are being treated with the AM, such as corneal epithelial defects, corneal ulcers, glaucoma, pterygium, and bullous keratopathy (Dua et al., 2004; Liu et al., 2010; Riau et al., 2010; Kesting et al., 2014) . Furthermore, the AM is also making its way in dermatology, where it can be used to cover burns and to treat chronic ulcers (Lo and Pope, 2009) , and in multiple surgical procedures, some of which already mentioned, and others, such as the prevention of post-operative adhesions. The increasing number of case studies will surely support the establishment of a routine use also in the latter two applications.
Clinical Trials
At the time this review was written, 95 clinical trials evaluating placental cells or AM (Figure 2 Recently published reports have provided consistent evidence of the therapeutic benefit of the AM graft. For example, the AM has been successfully used in patients with bullous keratopathy (NCT01926535, completed, Table 1), and the results suggested that the technique is safe and represents an efficient alternative to the use of therapeutic contact lenses for the relief of ocular pain in these patients (Venegas et al., 2014) . In a different study (NCT00659308, completed, Table 1), the AM was shown to be comparable to anterior stromal puncture in the management of pain in patients with bullous keratopathy (Paris Fdos et al., 2013) . When tested in patients with scleral thinning, the AM was not as effective as lamellar corneal and scleral transplantation (de Farias et al., 2014) , but a phase II/III trial is now enrolling patients for further testing (NCT00801073, Table 1 ).
The use of a dehydrated human amnion/chorion membrane Epifix ® (MiMedx ® ) has been reported to enhance healing and promote complete epithelialization of diabetic foot ulcers (NCT01552499, completed, Table 2 ) (Zelen et al., 2014) and to reduce wound size and improve healing also in patients with venous leg ulcers, both when compared to standard treatment (NCT01552447, completed, Table 2 ) . This same group also investigated the use of Amniofix ® (MiMedx ® ), a dehydrated human amniotic/chorionic membrane refined by a micronization process, in patients with plantar fasciitis (NCT01659827, completed, Table 3 ) (Zelen et al., 2013) . They reported reduced pain and improved physical and mental scores (evaluated by a health survey) versus controls. Interestingly, bovine AM (NCT01895374, completed, Table 2 ) has been tested for the treatment of laser-induced skin wounds, showing once again quicker epithelialization when compared to hydrocolloidtreated wounds (Min et al., 2014) , suggesting that xenogenic material can also be used in wound treatment.
As mentioned above, the interest in using cells isolated from different placental regions intensified in the twenty-first century. Different types of placenta-derived cells and factors are being tested in clinical trials. They come from either fetal placental tissues (such as amnion and chorion) or from maternal tissues (such as decidua). For example, PLX-PAD (PLacental eXpanded adherent stromal cells produced by Pluristem Inc.) are isolated from human placenta by enzymatic digestion of both maternal and fetal tissues (Ramot et al., 2009; Kranz et al., 2010) . PLX-PAD cells have been used in two clinical trials to treat critical limb ischemia (NCT00919958, completed; NCT00951210, completed) , and are now being tested for the treatment of intermittent claudication (NCT01679990, recruiting) and pulmonary arterial hypertension (NCT01795950, active) ( Table 5) . Thus far, no results have been published for the completed trials.
PDA-001/PDA-002 are culture-expanded mesenchymal-like cells produced by Celgene Cellular Therapeutics. The safety and efficacy of PDA001 cells have been studied in patients with Crohn's Disease (Mayer et al., 2013) (NCT01155362, completed; NCT01769755, completed) , ischemic stroke (NCT01310114, terminated by sponsor), pulmonary sarcoidosis (NCT01440192, FiGURe 2 | Registered clinical trials using placenta-derived cells or amniotic membrane. The search was performed in June 2015 on the U.S. National Institutes of Health clinical trials website using: placental-derived cells OR amniotic membrane, which resulted in 240 clinical trials. After excluding those with unknown status (which resulted in 196) and irrelevant ones, the search resulted in 95 clinical trials. For each disease application specified in small boxes, n = 1 unless otherwise specified. PAD, peripheral arterial disease; EB, epidermolysis bullosa; IPF, idiopathic pulmonary fibrosis; RA, rheumatoid arthritis; GvHD, graft versus host disease *Includes two published clinical trials not registered on NIH website (diabetes and multiple sclerosis).
terminated by sponsor), and active rheumatoid arthritis (NCT01261403, terminated) ( Table 5) . Published results obtained from the Phase I trial (NCT01769755) in patients with Crohn's disease (Mayer et al., 2013) show that out of the six patients treated with low dose and six with high dose, all low dose and two high dose patients responded to the treatment (defined as ≥70 point decrease from baseline in disease activity score). Some minor evidence of infusion-related events, fever, and headache were reported, but no patient withdrew from the study, and PDA001 was well-tolerated (Mayer et al., 2013) . A Phase II study (NCT01155362) investigating PDA001 in treatment-resistant Crohn's disease has just been completed, but results are not yet available. PDA001 cells have also been recently tested in patients with multiple sclerosis (Lublin et al., 2014) . The published results showed that in all 16 patients, none developed 5 or more new lesions in 2 consecutive monthly MRI scans during a 6-month follow-up. Some infusion-related adverse events, such as hematoma and swelling, occurred and settled without medication. This study is important in underlining the safety of placental cells in treating patients with multiple sclerosis, and encourages future studies to investigate therapeutic benefit in this physical and mental disabling condition.
PDA002 cells are currently being tested for the treatment of patients with diabetic foot ulcers and peripheral arterial disease (NCT01859117, active; NCT02460081, recruiting; NCT02264288, recruiting) ( Table 2) . Human placenta-derived stem cells (HPDSC, also produced by Celgene Cellular Therapeutics) are obtained from placenta perfusion after removal non-viable and red blood cells and tissue debris. These cells are cryopreserved without culture expansion . HPDSC will soon be investigated for treating neonates with severe hypoxic-ischemic encephalopathy (NCT02434965, not yet recruiting), and patients with hematological malignancies (NCT00596999, enrolling; NCT01586455, recruiting) ( Table 5) .
Placental-derived MSC are isolated from the placental tissues after the removal of umbilical cord and external membranes by enzymatic digestions (Prince Charles Hospital in Brisbane, Australia) (Brooke et al., 2009) . The safety of placental-derived MSC has been studied in patients with idiopathic pulmonary fibrosis (IPF, NCT01385644, completed). The results of this study have recently been published and show that intravenous infusion of 2 million cells per kilogram is safe in patients with moderate to severe IPF. Of note, the possibility of embolization of cells in the compromised pulmonary vascular bed, a major concern during this type of treatment, did not lead to major adverse clinical outcomes. Only minor, transient changes in hemodynamics and gas exchange, and only minor adverse events were observed (Chambers et al., 2014) .
Placenta-derived decidual stromal cells can be isolated by either trypsin digestion or tissue explants (Karolinska Institutet, Sweden). These cells derive from the decidua parietalis and are of maternal origin (Ringden et al., 2013; Erkers et al., 2015) . They have been tested in a pilot study in patients with hemorrhagic cystitis (NCT02172963, completed) and will soon be investigated in a different clinical trial to treat the same disease (NCT02174536, recruiting) ( Table 5) . A clinical trial is also due to begin for the treatment of patients with Graft versus Host Disease (NCT02172924, not yet recruiting). Moreover, a pilot study is currently recruiting patients with acute lung injury to evaluate the safety of placenta DSCs (NCT02175303, recruiting) ( Table 5) .
Remarkably, encouraging results have been published for studies using placenta-derived cells in patients with types II diabetes (Table 5) (Jiang et al., 2011) . In this Phase I study aimed at evaluating the safety of placenta-derived MSC, 10 patients with type 2 diabetes were given 3 intravenous infusions at the 1-month intervals. The authors reported that the mean insulin requirement was significantly reduced at the 3-month follow-up, and no side effects (fever, chills, liver damage) were documented. This trial could represent a turning point in the use of placental cells, since it is the first to document their use in patients with diabetes. A different study of particular interest was recently published investigating the immunogenicity of placenta decidual stromal cells in combination with AM in an 11-month-old patient with epidermolysis bullosa , showing improved healing of blisters and wounds, but at the same time warranting further investigations on the immunogenicity of these cells.
Notably, other clinical trials have and are currently investigating placental cell derivatives and, in particular amnion-derived cellular cytokine solution (ACCS) (Stemnion, Inc., Pittsburgh, PA, USA). ACCS is obtained from amniotic cell culture (Bergmann et al., 2009) , and contains factors relevant for wound healing, such as platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), angiogenin, TGF-β2, TIMP-1, and TIMP-2 (Steed et al., 2008) . It is currently being tested in patients with radiation-induced dermatitis (NCT01714973, active), and a separate trial is due to begin in patients with UV-induced burns (NCT02389777, not yet recruiting), ( Table 2) . Moreover, other trials are currently recruiting patients to test ACCS in dry eye syndrome (NCT02369861, recruiting, Table 1 ), and gingivitis (NCT02071199, recruiting, Table 3 ). Two trials, the first aimed at investigating ACCS in partial thickness wounds (NCT00886470), and the second in patients with deep burns (NCT01715012), were terminated due to difficulties in enrolling patients ( Table 2) .
Another placenta-derived product, amniotic membrane extract (AMX), which is based on lyophilized human AM for topical application, is under investigation in persistent corneal epithelial defects and has shown promising results for reducing epithelial defects (Kordić et al., 2013) .
MeCHANiSMS OF ACTiON: THe QUeST FOR SCieNTiFiC RATiONALe
Evidence of long-term survival with no signs of immune reaction was provided many years ago when the AM was used as an allograft under skin (Douglas et al., 1954) or in the peritoneal cavity (Trelford et al., 1974) . Subsequently, a glycoprotein from amnion was reported to be responsible for suppressing "foreign body" reactions by acting on lymphocytes and preventing lymphoblastogenesis (McIntyre and Faulk, 1979) .
Since then, numerous mechanisms have been put forth, either to explain the therapeutic effects of the intact or decellularized AM or those of isolated placental cells. Nowadays, the clinical potential of placenta-derived cells essentially relies on their paracrine mechanisms able to induce anti-inflammatory responses and re-epithelialization, and also to possess pro-or anti-angiogenic properties. Below we will briefly discuss these aspects.
Anti-inflammatory Properties
Among the paracrine actions underlying the anti-inflammatory effect of placenta-derived cells are their interactions with immune cells of innate and adaptive immunity. Indeed, many studies have reported the ability of placenta-derived cells to suppress the proliferation of activated T cells (Bailo et al., 2004; Chang et al., 2006; Wolbank et al., 2007; Prasanna et al., 2010; Kronsteiner et al., 2011a,b) , reduce Th1 inflammatory cytokines and induce T regulatory cells (Raicevic et al., 2011; Ohshima et al., 2012; Anam et al., 2013; Parolini et al., 2014; Pianta et al., 2015) , and target B lymphocytes (Li et al., 2005; Ma et al., 2012) . Furthermore, they can also influence antigen presenting cells by blocking differentiation of monocytes to dendritic cells (Magatti et al., 2009; Tipnis et al., 2010; Kronsteiner et al., 2011a,b; Saeidi et al., 2013; Banas et al., 2014; Abomaray et al., 2015; Donders et al., 2015; Magatti et al., 2015) , and induce M2 macrophage differentiation (Manuelpillai et al., 2012; Abumaree et al., 2013; Magatti et al., 2015) . Moreover, placenta-derived cells have been shown to inhibit neutrophils (Zhou et al., 2003; Li et al., 2005; Chen et al., 2014) , and natural killer cells (Ribeiro et al., 2013; Chatterjee et al., 2014; Li et al., 2015) .
Even though the underlying mechanisms are not completely understood, there are numerous studies which have put forth different hypotheses. Herein, we will briefly summarize them, since comprehensive reviews of the interactions between placenta-derived and immune cells have been described elsewhere (Parolini et al., 2009; Parolini et al., 2010; Manuelpillai et al., 2011; Parolini and Caruso, 2011; Prasanna and Jahnavi, 2011; Abumaree et al., 2012; Caruso et al., 2012; La Rocca et al., 2012; Kim et al., 2013; Silini et al., 2013; Insausti et al., 2014) . Cells from placental tissues have been shown to produce factors shown to dampen inflammation, such as interleukin (IL)-10 ( Kronsteiner et al., 2011a,b; Rossi et al., 2012; Abomaray et al., 2015; Magatti et al., 2015) , transforming growth factor (TGF)-β (Liu et al., 2012; Rossi et al., 2012; Pianta et al., 2015) , hepatocyte growth factor (HGF) (Najar et al., 2010; Kronsteiner et al., 2011a,b; Raicevic et al., 2011; Yamahara et al., 2014) , prostaglandin E2 (PGE2), (Whittle et al., 2000; Chen et al., 2010; Najar et al., 2010; Kronsteiner et al., 2011a,b; Raicevic et al., 2011; Liu et al., 2012; Rossi et al., 2012; Liu et al., 2014; Yamahara et al., 2014; Abomaray et al., 2015) , and indoleamine 2,3-dioxygenase (IDO) enzyme (Chang et al., 2006; Rossi et al., 2012; Anam et al., 2013; Donders et al., 2015) . Moreover, placenta-derived cells express negative co-signaling proteins B7H3, PD-L1 (CD274), and PD-L2 (CD273), (Petroff and Perchellet, 2010; Tipnis et al., 2010; Kronsteiner et al., 2011a,b; La Rocca et al., 2012; Abumaree et al., 2013; Wu et al., 2014) . HLA-G, a molecule known to have immune-regulatory properties through its interactions with immunoglobulin-like transcript (ILT) receptors (ILT-2, ILT-3, ILT-4), (Allan et al., 2000; Hunt et al., 2005) , has been reported to be secreted by a variety of placenta-derived cells (Lefebvre et al., 2000; Chang et al., 2006; Banas et al., 2008; Roelen et al., 2009; Kronsteiner et al., 2011a,b; Pratama et al., 2011; Anam et al., 2013; Donders et al., 2015) .
On another note, inflammatory cytokines/milieu have been shown to enhance the immunomodulatory properties of placenta-derived cells. For example, interferon (IFN)-γ has been shown to enhance their anti-proliferative properties on PBMC (Chang et al., 2006; Prasanna et al., 2010; Kronsteiner et al., 2011a,b; Donders et al., 2015) . IFN-γ has also been shown to increase HLA-G (Lefebvre et al., 2000; Banas et al., 2008; Kronsteiner et al., 2011a,b) , PD-L1 and PD-L2 (Banas et al., 2008; Petroff and Perchellet, 2010; Tipnis et al., 2010; Kronsteiner et al., 2011a,b) , and PGE2 production by placental cells (Chen et al., 2010) . Moreover, IL-1β, a potent inflammatory cytokine, has also been shown to enhance the immune modulatory properties of placental cells, such as through the induction of PGE2 secretion (Mitchell et al., 1993; Fukuda et al., 1999; Pomini et al., 1999; Chen et al., 2010 , Phillips et al., 2011 , and by enhancing their suppressive activities toward NK cells (Chatterjee et al., 2014) .
Pro-and Anti-Angiogenic Properties
The intact AM has been shown to produce an array of antiangiogenic factors. This property is epitomized in the use of intact AM for corneal surface reconstruction, where the use of AM decreases vascularization of the ocular surface through the production of anti-angiogenic proteins (Kim and Tseng, 1995; Shao et al., 2004) , such as pigment epithelium-derived factor (PEDF), (Kim and Tseng, 1995; Dawson et al., 1999; Shao et al., 2004) , tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 (Hao et al., 2000) , and thrombospondin-1 (TSP-1), (Zaslavsky et al., 2010) . The intact AM has also been reported to have a large amount of ECM proteins (i.e., laminin-1, laminin-5, fibronectin), which are involved in the suppression of neovascularization in the cornea (Fukuda et al., 1999) .
Decellularized AM, whereby amniotic epithelial cells are eliminated and the cytokine-rich ECM is retained, has been shown to maintain anti-angiogenic properties (Tseng et al., 2004) .
Furthermore, epithelial and mesenchymal cells isolated from the AM have also been shown to produce anti-angiogenic factors, such as TIMP-1, TIMP-2, TSP-1, and endostatin (Rowe et al., 1997; Hao et al., 2000) .
On the other hand, pro-angiogenic properties have also been attributed to the AM, which can be considered important contributors to its wound healing and regenerative capabilities. For example, cytokines known to promote angiogenesis have been found in dehydrated human amnion/chorion membrane, such as angiopoietin-2, epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), heparin binding epidermal growth factor (HB-EGF), HGF, platelet-derived growth factor BB (PDGF-BB), placental growth factor (PlGF), and VEGF (Koob et al., 2014b) . Recently, pro-angiogenic factors have been found in conditioned medium from MSC isolated from the AM, which was shown to not only limit infarct size but also promote capillary formation at the infarct border zone when injected into infarcted rat hearts (Danieli et al., 2015) . These apparently contradictory properties could give rise to the importance of understanding the impact of the microenvironment in determining the pro-or anti-angiogenic abilities of the AM and placental cells.
Promotion of epithelialization
Another important, and well-documented, property of the intact AM is its ability to promote re-epithelialization. The intact AM has been used as a basement membrane to promote epithelial cell migration, differentiation, and prevent epithelial cell apoptosis (Dua et al., 2004) . In addition, it produces factors that can stimulate epithelialization, such as bFGF, HGF, and TGFβ (Dua and Azuara-Blanco, 1999; Koizumi et al., 2000) . The intact AM also produces factors that support the growth and differentiation of stem and progenitor cells (Meller et al., 2000; Meller et al., 2002 , Insausti et al., 2010 , such as keratinocyte growth factor (KGF) , supporting its use as a progenitor cell niche (Tseng et al., 2004) .
Furthermore, dehydrated human amnion/chorion membrane, which preserves ECM composition and retains an array of cytokines, chemokines, and growth factors naturally present in the native tissue, was found to preserve re-epithelialization properties (Koob et al., 2014a) .
Studies performed on the AM denuded of epithelial cells have shown significantly lower levels of bFGF, HGF, EGF, and KGF, when compared to intact AM, suggesting an epithelial origin of these factors (Koizumi et al., 2000) . Among other ECM proteins found in AM, fibronectin, laminins, and collagen IV and VII have also been reported, which can in turn promote epithelial adhesion and migration (Fukuda et al., 1999; Lobert et al., 2010) .
Cells of the AM have also been suggested to promote epithelialization through secretion/production of factors, which can direct migration, proliferation, and differentiation of keratinocytes. In particular, human amniotic mesenchymal cells (hAMSC) and epithelial cells (hAEC) can secrete factors crucial for wound healing. hAMSC highly express EGF, a factor known for its role in keratinocyte and fibroblast migration, IL-8 that promotes re-epithelialization by increasing keratinocyte proliferation and migration, and IGF-1 that is involved in wound closure by promoting the growth of endothelial cells, dermal fibroblasts, and keratinocytes (Kim et al., 2012) .
High expression of EGF and PDGF has also been reported in hAEC, the latter of which stimulates the chemotaxis and proliferation of fibroblasts, and is a critical regulator of ECM deposition in healing wounds (Jin et al., 2015) . Both hAMSC and hAEC have been shown to engraft into the wound area thus potentially enhancing their paracrine effects and, furthermore, they could directly participate in re-epithelialization by their trans-differentiation into keratinocytes (Kim et al., 2012; Jin et al., 2015) .
CONCLUDiNG ReMARKS
Although there are still many open questions regarding the sine qua non conditions for the clinical use of placental cells (Fierabracci et al., 2015) , the increasing number of clinical trials underlines the interest in using them. Ongoing and future studies will be crucial in helping define their molecular mechanisms, and establishing the true value of placental derivatives (AM, cells, or molecules they release). These studies will undoubtedly unveil additional applications in the field of regenerative medicine. Studies on placental derivatives available thus far have surely contributed to the vision of regenerative medicine, not only based on cell replacement but also on the importance of their paracrine effects, which could promote endogenous tissue regeneration.
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